Skip to main content

Deciphera Pharmaceuticals, Inc.

DCPHDelisted Jun 11, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001654151

Deciphera Pharmaceuticals, Inc. was delisted on Jun 11, 2024; its insiders filed their last Form 4 on Jun 11, 2024; 177 institutions reported holding it in 13F filings for Q1 2024, worth $943.7M in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
177
Q1 2024, +13 vs. previous quarter
13F value
$943.7M
Reported value at the end of Q1 2024
Superinvestors holding
0
At the end of Q1 2024

From SEC filings, in USD.

Revenue, FY2023
$163.4M
+21.9% year over year
Net income, FY2023
-$194.9M
No comparable prior period
Free cash flow, FY2023
-$147.5M
No comparable prior period
Revenue, Q1 FY2024
$45.0M
+34.5% year over year

Revenue flow, FY2023

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2023: $194.9M (119.3% of revenue).

Superinvestors holding DCPH, Q1 2024

Go to the superinvestors tab

No superinvestor reported holding DCPH at the end of Q1 2024.

Latest insider trades

See all insider trades

Open-market purchases and sales by Deciphera Pharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 20, 2024 (view filing)Feb 164 daysKelly Thomas PatrickChief Financial OfficerSSale−3.01K$15.62−$47.0K−3.6%80.3K after
Feb 20, 2024 (view filing)Feb 164 daysMartin Daniel C.Chief Commercial OfficerSSale−2.27K$15.62−$35.4K−4.0%55.1K after
Feb 20, 2024 (view filing)Feb 164 daysSherman Matthew LEVP & Chief Medical OfficerSSale−2.62K$15.62−$40.8K−2.3%108.7K after
Feb 20, 2024 (view filing)Feb 164 daysPitman JamaSVP, Chief Development OfficerSSale−2.27K$15.62−$35.4K−3.2%68.0K after
Jan 18, 2024 (view filing)Jan 162 daysSherman Matthew LEVP & Chief Medical OfficerSSale−2.44K$14.47−$35.2K−2.5%94.1K after
Jan 18, 2024 (view filing)Jan 162 daysPitman JamaSVP, Chief Development OfficerSSale−1.62K$14.47−$23.5K−3.1%50.6K after
Jan 18, 2024 (view filing)Jan 162 daysKelly Thomas PatrickChief Financial OfficerSSale−2.44K$14.47−$35.2K−3.6%66.1K after
Jan 18, 2024 (view filing)Jan 162 daysMartin Daniel C.Chief Commercial OfficerSSale−1.62K$14.47−$23.5K−3.3%47.7K after
Dec 14, 2023 (view filing)Dec 131 dayHoerter Steven L.President and CEOSSale−30.7K$15.37−$471.3K−29.6%72.8K after
Dec 14, 2023 (view filing)Dec 131 dayPitman JamaSee RemarksSSale−1.66K$15.37−$25.5K−3.1%52.2K after

Top 10 13F holders, Q1 2024

See all 177 holders

The largest institutional positions in Deciphera Pharmaceuticals, Inc. at the end of Q1 2024; share changes are against Q4 2023.

Institutions holding DCPH in Q1 2024
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock Inc.5,994,276$94.3M0.00%+18,010+0.3%Added
Armistice Capital, LLC5,900,000$92.8M2.47%+700,000+13.5%Added
Redmile Group, LLC5,296,643$83.3M3.06%+495,103+10.3%Added
Deerfield Management Company, L.P. (Series C)5,127,270$80.7M1.40%−660,754−11.4%Reduced
Vanguard Group Inc4,565,044$71.8M0.00%+163,408+3.7%Added
State Street Corp3,098,806$48.7M0.00%+627,993+25.4%Added
Goldman Sachs Group Inc1,962,841$30.9M0.01%−344,634−14.9%Reduced
Dimensional Fund Advisors LP1,606,132$25.3M0.01%+44,478+2.8%Added
Morgan Stanley1,539,826$24.2M0.00%−776,607−33.5%Reduced
Polar Capital Holdings Plc1,500,000$23.6M0.14%−350,000−18.9%Reduced